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The products of the major histocompatibility complex (MHC) 2 class II genes 
are surface glycoproteins, consisting of noncovalently associated a  and 13 chains, 
which are involved in the presentation of antigen to T  cells during the immune 
response. The class  II products are highly polymorphic and this polymorphism 
is the basis  for the restriction of antigen presentation to T  cells of the same 
haplotype, as well as for haplotype-specific variation of the immune response to 
different antigens (1).  Thus, the polymorphic regions of class  II products are 
implicated in interactions with T  cell receptor and antigen. They also define the 
epitopes responsible for serologic and immunochemical specificities. 
The region encoding the human class II or Ia antigens represents a complex 
genetic system of at least three subregions, HLA-DP, -DQ, and -DR, which have 
recently been further divided into multiple individual loci. There are currently 
estimated to be seven 13 chain genes (2) and five or six ot chain genes (3, 4). This 
multiplicity at the genetic level correlates with the existence of multiple a  and 13 
chains at the cell surface (5, 6). 
Because of this complexity, an understanding of the nature and functional role 
of each of these molecules and their correlation with established serological and 
immunochemical specificities has become an important challenge. One approach 
is based on the possibility of expressing individual class  II genes independently 
by DNA-mediated transformation. We have reported (7) the construction of a 
mouse fibroblast cell line transformed with one of the DR-/3 chain genes, the 
DR-o~ chain gene, and the gene for the DR-associated invariant chain. This cell 
line synthesizes HLA-DR antigen and expresses it on the surface where it can be 
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identified  with  anti-DR  antibodies.  In  this  paper  we  analyze  the  DR  antigen 
product of a  single  DR-/3 chain  locus as expressed in  these transformed mouse 
cells. 
The polymorphism associated with the  DR antigens is predominantly carried 
by the/3 chain. Two kinds of polymorphic determinants have been attributed to 
HLA-DR products:  (a) the  DR antigen proper, controlled by a  highly polymor- 
phic DR-/3 chain gene, of which at least  14 distinct allelic specificities have been 
described  so far,  and  (b)  supertypic  specificities  that  are  shared  by groups  of 
different haplotypes. Two of these supertypic specificities, BR3 and BR4,  have 
been  shown  to  be  carried  by  /3  chains  distinct  from  those  carrying  the  DR 
specificity (8, 9).  We show here that the product of the cloned DR-/3 gene used 
in the transformation of mouse cells (7) carries one of the supertypic specificities 
that  has  been  attributed  to  a  specific locus  (8).  This allows  us  to  establish  the 
correlation  between  a  given  serological  specificity  and  the  DR-/3  chain  gene 
encoding that specificity. The evolutionary implications of these results are also 
discussed. 
Materials and  Methods 
Sequence of the DR-~ Chain  Gene.  The first, second, and transmembrane domains of 
the DR-B chain gene used for the transformation were subcloned in M 13 phage vectors 
(10).  Sequences were performed by the chain  termination  method (11).  Only the first 
domain and transmembrane region were entirely sequenced. 
Southern Blotting for Typing the DR-~ Chain Gene Used  for the Transformation.  Southern 
blot hybridization was performed basically as described by Jeffries and Flavell (12). DNA 
from the cell line from which the DR-~8 chain gene had been cloned (typed as DR4,w6) ~ 
as well as DNA from (a) a DR4 homozygous typing cell,  (b) a DRw6 homozygous typing 
cell, and (c) the genomic DR-/3 chain clone, were digested with Hind III, electrophoresed, 
and  transferred  to  nitrocellulose.  The blot  was hybridized  using a  genomic fragment 
corresponding to the second domain and flanking intron sequences. Hybridization was in 
4x standard sodium citrate (SSC) (1 ×  SSC: 0.15 M NaCI, 0.015 M sodium citrate), 0.1% 
sodium dodecyl sulfate,  and  5x  Denhard's solution  (lX  Denhard's:  0.1%  Ficoll,  0.1% 
polyvinyl-pyrilidone, 0.1% bovine serum albumin [BSA]) at 68°C. The final wash was in 
0.25x SSC at 68°C. 
Antibody-binding Assays.  The transformed mouse fibroblasts and the parental DR4,w6 
cell  line  were  grown,  harvested,  and  washed  in  phosphate-buffered  saline  (PBS)/BSA 
(0.15 M NaCI, 0.01  M sodium phosphate, pH 7.2, 0.2% BSA). They were then aliquoted 
into  microtiter wells,  pelleted,  and  reacted  with  the  appropriate monoclonal antibody 
(mAb) for 2 h  at 4°C with agitation. The cells were then washed and reacted with ~2sI- 
labeled sheep anti-mouse Ig for 2 h  at 4°C with agitation.  After further washing they 
were resuspended and counted. All assays were performed in triplicate. 
In  Vivo Labeling  and Analysis.  Cells  were  in  vivo labeled  with  [~SS]methionine  and 
lysed, and the lysates were reacted with the appropriate mAb. After precipitation using 
protein A-Sepharose, the precipitates were analyzed by two-dimensional electrophoresis 
as described (13).  For the B cell line, the supernatants were then reprecipitated with the 
same mAb to assure that the first precipitation was quantitative, followed by a precipitation 
with the second mAb of the pair. 
Analysis of Antigenic Specificities.  An inhibition assay was used based on the reaction of 
antisera or antibodies with  I-labeled class II molecules. These were purified from the 
membranes of lymphoblastoid cell lines according to a previously described method (14). 
The old  DRw6 nomenclature  is retained  because the  cells used have not  been  analyzed to 
determine their new typing. We use the local names BR3, BR4, and DRpub3 to describe certain 
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The following cell lines were used as starting material for class II molecule purification: 
U698M  (DR2,4;  DR3  =  BR4;  DQwl,3)  and  Daudi  (DRw6;  DR52  (DRpub3  +  BR3); 
DQwl). Class II molecules from U698M were used either as such or after digestion with 
papain (EPD preparation). Such treatment has been showri to abolish the DR4 specificity 
(15).  The untreated  U698M  preparation  was  used  for testing  DR4,  the  U698M-EPD 
preparation for testing BR4 (DR53). 
Alloantisera were kindly provided by Dr. G. B. Ferrara, Genoa, Italy. Their specificity 
has been previously defined as follows: Fe59/15,  anti-DR4 (16);  Fe27/26,  anti-DR7  + 
BR4 (17); Fe88/37, anti-MT2 (18). mAb MCS7 was also used, which recognizes an MT2- 
like  specificity that  is  present  exclusively on  DR,  and  not  BR,  molecules  (9).  Rabbit 
antiserum anti-human Ia 7147 was raised against a preparation of Ia molecules purified 
from Daudi cells and has been shown to contain antibodies reactive with both isolated 
and fl chains (19). 
The binding inhibition assay was performed as follows: cells were iysed with 2% Renex 
30 at a  cell concentration  of 20  ×  106/ml.  Varying dilutions  of each cell  lysate were 
incubated with a fixed amount of antibody for 24 h at 20°C and again, for 24 h at 20°C, 
with an aliquot of ~SI-labeled class II preparation. The reaction mixture (100 ~1) contained 
0.075  M Tris-HCl, pH 7.8,  0.2%  Renex 30, and 0.02% BSA. Then, sheep anti-human 
(or rabbit or mouse) Ig serum was added at equivalence and incubated 1 h at 37°C. The 
resulting  immune precipitate was washed and  the  radioactivity determined.  A  control 
with normal serum was included in each assay. Results are expressed as the percentage 
decrease (percent inhibition) of maximum binding, i.e., the radioactivity precipitated in 
the absence of inhibitor. 
Results 
Amino Acid Sequence,and Haplotype of the DR-13 Chain Expressed in Transfected 
Mouse Fibroblasts.  The use of cells transformed with a single cloned DR-13 chain 
gene  in  biochemical,  serological,  and  functional  studies  has the advantage that 
all the results can be referred directly to the protein sequence derived from the 
DR-/3 chain  gene  used  for  the  transformation.  We  have  determined  that  the 
nucleotide sequence of the exon encoding the polymorphic first domain of this 
DR-/3 chain  gene  is  identical  to  that  of a  complementary  DNA  (eDNA)  clone 
isolated from the  same cell  line  which  we had  sequenced  previously (20).  The 
amino acid sequence of the first domain (Fig.  I) is extended to include the entire 
/3 chain by using the eDNA data. 
First  Domain 
S  S 
Genomlc  RF  LELL-~S  ECHFFNGT  ERVRF  LERKFHN  QEEYARF  DS  DVGEY  RAVRELGRPDAEY~N  SQK  DLLEQK  RGQVDNYC  RlINY  GWE SF  TVQRR 
cDNA  GDTRPRFLELLKS  ECHFFNGTERVRFLERI]FHNQEEYAJRFDSDVCEYRAVRELGRPDAEYWNSQKDLLE~KR~VD~C~G~ESF~Q~ 
cDNA 
Second  Domain 
S  S 
VHPQVTVYPAK  TQPLQHnNLLVCSVSGFYPGS  I EVRWFRNGQEEI~AGWSTGLI  QNGDWTFQTLVMLETFPRSGEVYTCQV~PSVTSPLTVEW 
Trau  smembrane/Cyt  op  lammic 
eDNA  SARS  ESAQSKMISGVGGFVLGLLFLGAGLF  I  YFRNQK  GHS  GLQPTGF  LS 
FIGURE I.  Amino acid  sequence of the first  domain of the DR-fl  chain gene used for 
transfecting  mouse L cells.  The amino acid  acid  sequence is extended using  the published 
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Since  the  gene  was  cloned from a  DR4,w6  heterozygous cell  line,  we  used 
Southern blot  hybridization  to determine  whether  it belonged  to  the  DR4  or 
DRw6 haplotype. DNA from a  DR4,4 homozygote, a  DRw6,w6 homozygote, or 
from the DR4,w6 cell line from which the gene was isolated, together with DNA 
from the cloned gene itself, was digested with Hind III, electrophoresed, trans- 
ferred onto nitrocellulose, and hybridized with a  probe specific for the second 
domain  of the  DR-/3 gene.  The  DR4  and  DRw6  patterns  can  be easily distin- 
guished (Fig.  2).  The DR4,w6  pattern is the sum of the bands present in  DR4 
and  DRw6  DNA.  The gene used for the transformation  experiment (Fig.  2A) 
gave a  Hind III fragment characteristic of DRw6 and is therefore of the DRw6 
haplotype. Neither DP-/3 nor DQ-~ hybridized with the probe. 
Analysis of the DR Gene Products Synthesized in  Transfected Fibroblasts by mAb. 
The immunochemical analysis of the products of a  single DR gene expressed in 
mouse  fibroblasts  had  two  objectives,  to  investigate  the  specificity of anti-DR 
mAb and to establish  the fidelity of the gene expression in transformed mouse 
fibroblasts. 
There have been several reports (21-24) that certain mAb recognize different 
subsets of DR molecules. Since the members of these subsets could represent the 
products  of different  DR  loci it  was  important  to compare  the  reactivities  of 
FIGURE 2.  Identification of the haplotype of the DR-/~ chain gene used in DNA-mediated L 
cell transformation by Southern  blot analysis. DNA from reference cells, the DR4,w6 line, 
and the DR-3 genomic clone were digested with Hindlll, and analyzed by Southern  blot 
hybridization. The typing of cells whose DNA was analyzed is given above each lane. (A) The 
DR-/~ genomic clone. GORSKI  ET  AL.  109 
these mAb. We investigated two pairs of antibodies,  L243 and L227  (21) and 
D1 and D4 (22)i by cell-binding studies using iodinated protein A. D1 and L243 
showed (Fig. 3) a concentration-dependent increase in binding to the transformed 
fibroblasts, homologous to the binding of the parental cell line from which the 
DR-/3 gene was  derived.  L243  is  reported (21,  23)  to  be a  DR-specific mAb 
whereas L227 only precipitates a subset of DR molecules. D1  and D4 are both 
reported to immunoprecipitate nonoverlapping subsets of DR  molecules (22). 
Consequently, the product of this DR-/3 gene corresponds to the Dl-precipitable 
subset but not to the L227 or to the D4 subsets. These results also confrm that 
the gene products expressed in  mouse fibroblasts are recognized as true  DR 
molecules. 
To extend the correlation between the unique  DR-/3 gene and the subsets 
defined immunochemically, the in vivo labeled products from the fibroblasts and 
the parental B cell line were immunoprecipitated and analyzed by two-dimen- 
sional electrophoresis. The choice of mAb, D 1 and D4, was based on the results 
of the previous binding experiments. The results are shown in Fig. 4. The D 1 
mAb precipitated three  intense /3 chain  spots  from the  DR4,w6  line (Fig.  4, 
broad  arrows),  which  were also  precipitated  from the  transfected fibroblasts 
(T229). D4 precipitated five major/3 chain spots from the parental line, of which 
three migrated in the same position as those precipitated by D1.  None of the 
D4-specific parental spots were seen in the transformed fibroblasts. Both the D 1 
and D4 mAb precipitated low amounts of protein from the transfected mouse 
fibroblasts that did not correspond to products made by the parental B cell line 
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FIGURE 3.  Binding assays using the DR-transfected L  cells and the parental DR4,w6  cell 
line. The mAb used are shown in the corner of each graph. The binding to nontransformed 
mouse fibroblasts (average, 500 cpm) has been subtracted from each point. 1 10  ANALYSIS  OF  HLA-DR  EXPRESSED  IN  TRANSFORMED  MOUSE  CELLS 
FIGURE 4.  Two-dimensional gel  analysis of the  immunoprecipitated products of in  vivo 
labeled cells. The cell and mAb used are indicated. T229,  DR-transfected mouse L cell line; 
DR4/6, B cell line from which the DR-13 gene used for transfection was derived. The thick 
arrows point to spots present only in D4 precipitations, the medium arrows to spots present in 
both  D1  and  D4  precipitations, and  the  thin arrows  to  spots only  precipitated from  the 
transformed fibroblast, irrespective of antibody used. 
(Fig. 4, thin arrows). These faint spots are probably posttranslationally modified 
DR-/3 chains not representative of DR-t3 chains found in B cells.  The absence of 
dose-dependent binding of D4 to the transfected fibroblasts indicates that either 
these molecules are not present at the cell surface or they are responsible for the 
low-level nonspecific binding. 
To ensure that the two mAb really distinguished nonoverlapping subsets of 
DR, the supernatants from the B cell immunoprecipitations were reacted with 
the  second  of the  paired  mAb  (see  Materials  and  Methods).  When  the  D1 
supernatant was precipitated with D4, the resulting 2D gel was identical to the 
direct  D4  precipitation.  Identical  results  were  obtained  with  D1  (results  not 
shown). This indicates that the three spots (Fig. 4, broad arrows) common to D1 
and D4  represent nonoverlapping sets of DR  molecules. The results with the 
transfected fibroblasts confirm this. If the spots precipitated from the B cell and 
the fibroblast (Fig. 4, broad arrows) are a subset of D4, then D4 should precipitate 
these same spots from the transfected fibroblasts. It does not. Therefore, the DR 
polypeptide encoded by the gene used here is precipitated by D 1 and runs in the GORSKI  ET  AL.  ] 1 1 
same position on a  2D gel as another DR product found in the B cell line. This 
other polypeptide is precipitated by D4. 
As  in  the  case of the  parental  B  cell  line,  we  observed two o~ spots in  the 
transfected fibroblasts although  only a  single a  DR gene had been introduced 
into the cell. The lack of association of the invariant chain with Dl-precipitable 
DR chains  (Fig.  4) will  be discussed in  detail elsewhere (M.  Strubin, J.  Gorski, 
and B. Mach, manuscript in preparation). 
Inhibition Studies for Typing the Transfected Cells and Correlation With Serological 
Supertypic Specificities.  The  transfected  fibroblasts were  used in  an  inhibition 
assay (Fig.  5) to determine their serological typing and to see if the DR-B gene 
present was responsible for any of the reported DR-associated serological super- 
specificities. The assay consisted of labeling surface Ia molecules from a  target 
cell and determining  whether the transfected fibroblasts inhibited  the reaction 
of the  antigen  with  a  number  of antisera  or  antibodies.  For  each  series  of 
experiments, the labeled antigen, and the sera or antibody with its specificity are 
given (Fig. 5). For each pair of antigen and serum, the inhibitors were the HHK 
cell  line  (DRw6,w6),  the  DR4,w6  parental  B  cell  line,  and  the  transfected 
fibroblasts. In Fig. 5 A, the antigen was the Ia surface product of cell line U698M 
(DR2,4) and the antibody was a rabbit anti-human  Ia serum with broad specificity 
for class  II  antigens.  Both  HHK and  the  parental  line  inhibited  at  equivalent 
concentrations  (Fig.  5A).  The  transformed  fibroblasts  inhibited  at  a  10-fold 
greater concentration  and a  nontransformed  mouse cell line showed negligible 
inhibition.  The  difference in  concentration  needed  for  inhibition  reflects not 
only the different concentration of DR molecules on the cell membrane and the 
nonclonai nature of the transformed cells, but also the overall complexity of the 
Ia molecules on the B cells compared with the transfected fibroblasts. 
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FIGURE 5.  Test of antigenic specificity. Inhibition reactions performed as in Materials and 
Methods except that incubation times of the rabbit anti-human Ia serum (Ra H la) (A) were 
shortened to 1 h at 37°C. The following volumes of antisera were used: rabbit anti-Ia (serum 
7147), 0.016/~1; Fe59/15, 7 #1; Fe 27/26,  1 ttl; Fe88/37, 3 #l. -15,000 cpm aliquots of Daudi 
and  U698M  and  7,000  cpm  of  U698M-EPD  were  used.  Inhibitors:  HHK  (DRw6,6)  (U1); 
DR4,w6 (A); 22/9 (transfected fibroblast) (O); untransfected fibroblasts (0). 112  ANALYSIS  OF  HLA-DR  EXPRESSED  IN  TRANSFORMED  MOUSE  CELLS 
Fig. 5B used the same DR4,2 antigen but an anti-DR4 serum. The inhibition 
was evident, as expected, only with the DR4,w6 parental cells. 
Fig.  5 C  used papain-treated U698M  cells as targets. The papain treatment 
destroys the DR4 determinant but leaves intact a supertypic specificity associated 
with DR4 and DR7, called BR4 (DRw53).  The sera were anti-DR7 and -BR4. 
Again, only the  DR4,w6  cell line acted as inhibitor to this test system, ruling 
against either a  DR4  specificity or a  BR4 superspecificity on the transformed 
mouse line. 
In Fig. 5 D, the target antigen was Daudi (DRw6) and the serum was anti-MT2 
(DRw52). An anti-MT2 response indicated the presence of supertypic determi- 
nants DR public3 (DRpub3) and BR3. In fact, MT2 is composed of two specific- 
ities that have similar association patterns (DR3,5,w6,w8,w 13) but are localized 
on different DR subsets (8). There was inhibition by the transformed fibroblasts 
(Fig.  5D),  strongest  with  HHK,  half as  strong  with  the  DR4,6.  A  10-fold- 
increased concentration of the transfected fibroblasts was necessary to reach a 
plateau of inhibition. Interestingly, this plateau was not at 100%, implying that 
there are some determinants on Daudi that were not being blocked by the DR- 
expressing fibroblasts. 
Since two superspecific determinants can be defined by an anti-MT2 response, 
it was of interest to see if  the DR-13 chain expressed on the fibroblast corresponded 
to  the  DRpub3  or  BR3  superspecificity,  mAb  MCS7,  directed  against  the 
DRpub3  determinant, was used in  the  inhibition assay shown in  Fig.  6.  The 
HHK and the parental lines were potent inhibitors, but the transfected mouse 
fibroblasts showed no inhibition. The product of the DR-B chain gene expressed 
in the mouse fibroblast thus corresponds to the BR3 superspecificity. 
Discussion 
Cells that, as the result of DNA-mediated transformation with cloned class II 
genes, express only one of the multiple human Ia products, are useful experi- 
mental  models.  They  can  be  used  to  correlate  antibody specificities  to  the 
products of individual loci and to study the functional aspect of individual class 
II genes. They can also provide a  means of raising specific mAb for any single 
class II molecule. 
The present work deals with the correlation of a  single DR-B chain gene to 
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FIGURE 6.  Inhibition assay with MCS7 mAb. A 5% dilution of MCS7 culture fluid (concen- 
trated fivefold) was used.  10  #1  of normal mouse serum was added as carrier. The labeled 
antigen preparation (15,000 cpm) was from Daudi cells (DRw6). Inhibitors are as in Fig. 5. GORSKI  ET  AL.  1 13 
different serological and immunochemical properties of DR-/3 chains. The DR-/3 
chain  gene  used here  is one of three  DR-/3 chain  genes present  in  the  DRW6 
haplotype and  only one of at  least  seven class  II  /3 chain  genes in the human 
MHC. We have determined (Fig.  1) the primary structure of the product of this 
DR-/3 chain  gene and identified the gene as belonging to the DRw6 haplotype 
by both molecular and serological approaches. 
The differential precipitation of the DR-/3 chain indicates that, at least for the 
DRw6 haplotype,  some locus-specific products  can  be differentiated  by mAb. 
This kind of analysis has been extended recently (25) to mAb of the panel from 
the  First  International  Workshop on  Monoclonal  Antibodies  to Human  MHC 
Class II Antigens. 
Our two-dimensional gel analysis of the products of the transformed fibroblasts 
showed that  the  three  predominant  forms of/3 chains expressed in  the  trans- 
formed fibroblast correspond to molecules present in the parental  B cell. The 
faint spots, precipitated indiscriminately by either D 1 or D4 mAb from fibroblasts 
but  not  from  parental  B  cells,  could  reflect  DR-/3  chains  that  result  from  a 
processing specific to mouse fibroblasts. From the low intensity of these spots it 
is clear that they are only a  small portion of the products.  One feature of this 
system is the fidelity with which most chains are processed in mouse fibroblasts. 
The presence of two a  chain spots in both B cells and in fibroblasts transformed 
with a unique a  chain gene indicates that these are alternate forms derived from 
one gene. 
From  the  two-dimensional  gel  analysis,  it  is evident  that  the  products  of a 
single locus can give rise to multiple spots representing several forms of/3 chains. 
The gel pattern of the products of one DR locus was complex, and the complexity 
was much greater in experiments with normal cells where the products of all the 
DR loci were analyzed together. 
The  identity  of the  epitopes responsible for serological  specificities and  the 
distribution  of these epitopes across the products of different  DR-/3 chain  loci 
are questions amenable to study using transformed cells. We have investigated 
the ability of DR-positive mouse fibroblasts to inhibit interactions between cells 
of known  DR specificity and various sera or antibodies.  DR4- or BR4-specific 
sera were not blocked by the fibroblast membrane preparations.  This indicates 
that the gene used for transformation does not belong to the DR4 haplotype. 
The specificities defined by the DRw6 haplotype were then analyzed.  DRw6 
cannot be considered as a defined antigen since antisera reacting specifically with 
DRw6 have  not  yet been  found.  Thus  the only testable specificity was MT2, 
which is a supertypic specificity, that is, associated with several haplotypes, DR3, 
B,  w6,  w8,  and  w12.  Most  supertypic  specificities  have  been  shown  to  be 
correlated  with  distinct  class  II  subregions,  either  DR or  DQ.  MT2  has been 
more difficult to define. Markert and Cresswell (26) first recognized the existence 
of "MT2 +  DR" and "MT2 only" molecules, which was subsequently confirmed 
(9,  27).  MT2  thus  can  be  considered  as  a  bi-locus  specificity with  both  loci 
probably belonging to the DR subregion (9). The two MT2 supertypic determi- 
nants have been called DRpub3 and BR3 (8). Our experiments have shown that 
the DR-/3 gene studied here encodes the MT2 supertypic specificity. The  MT2 
nature of this gene has been corroborated by binding studies (28) with 7.3.19.1, 1 14  ANALYSIS  OF  HLA-DR  EXPRESSED  IN  TRANSFORMED  MOUSE  CELLS 
a  mAb directed against  MT2.  It remained to be seen whether this gene corre- 
sponds to the locus carrying the DRpub3 determinant  or the BR3 determinant 
(8).  Presently,  the  only  way to  differentiate  between  these  two possibilities  is 
based on reactivity with a polymorphic mAb, MCS7, that recognizes the DRpub3 
determinant  (9).  The  failure  of transfected  mouse  cells  to  inhibit  an  MCS7 
reaction  indicates  that  the  MT2-positive  DR-~  chain  produced  by these  cells 
carries only the BR3 determinant.  This is unambiguous evidence that the locus 
postulated to encode the BR3 determinant is one of the DR loci. 
Our results, along with Southern blotting data of the various DR haplotypes, 
suggest a  simple  model  for the  evolution of supertypic  families based on  the 
existence  of  several  DR-~  chain  loci  that  show  different  degrees  of  allelic 
polymorphism. Southern  blot data (C. DePreval, G. Angellini,  B. Boogh, G. B. 
Ferrara, and B. Mach, manuscript in preparation) has shown that the DNA from 
haplotypes  within  a  supertypic  group  often  share  most and  sometimes all  the 
same restriction  fragments.  Such conservation of restriction sites argues heavily 
in favor of evolutionary relatedness. The present data assign a given supertypic 
specificity,  BR,  to  a  distinct  DR-t8  chain  locus.  DNA  restriction  fragments 
associated with  this gene  were also seen  in  the DR3 and  DR5 haplotypes.  We 
postulate  that  all  the  DR haplotypes  that  presently  define a  given  supertypic 
group arose from a  common progenitor and that  the different DR loci within 
these  haplotypes  subsequently  diverged  at  various  rates.  This  evolution  may 
proceed by the addition  of new determinants  to those already present or by a 
concomitant  destruction  of old determinants  during  the  mutation  events that 
give rise to the newer determinants.  The most polymorphic locus today defines 
individual  DR specificities (e.g.,  DR3,  DR5, and  DRw6).  It remains  linked  to 
other less polymorphic loci, which constitute the supertypic loci. 
There are precedents  for the existence of more or less polymorphic regions 
within the class II subregions of both mouse and man. In the mouse, a comparison 
of restriction maps of clones from different baplotypes shows regions of little or 
no polymorphism and other regions of high polymorphism (29). In man, genomic 
blotting analysis (30) indicates that the DR subregion shows a much higher level 
of restriction  site polymorphism than the DQ region, whereas the DP region is 
relatively nonpolymorphic by this criteria (31). Therefore, it is likely that,  even 
within the DR subregion, the different DR loci could show different degrees of 
polymorphism. 
If the locus carrying the supertypic specificity is less polymorphic than  other 
DR loci, one would predict that  molecular analysis of other haplotypes within 
the MT2 supertypic group will show the existence of a  DR-~ chain gene that is 
very similar and perhaps  identical  to the one analyzed here.  This gene should 
encode the protein carrying the BR3 supertypic specificity of these other haplo- 
types. 
Summary 
Using a  mouse cell line transformed with and expressing a single HLA DR-a 
and DR-/~ chain gene, we present evidence that  the product of the DR-~ chain 
gene carries a supertypic determinant,  BR3, previously defined by serology. The 
amino acid sequence of this ~ chain gene is determined from the DNA sequence. GORSKI  ET  AL.  1 15 
Another  DR-associated  supertypic  specificity  defined  by  monocional  antibody 
MCS7  was  not  encoded  by this  DR-3 chain  gene.  This  provides  formal proof 
that a  supertypic specificity can be associated with a  product of a  distinct  DR-/3 
locus.  We  propose  that  haplotypes sharing  such  specificities are  evolutionarily 
related. 
We  wish  to  thank  Claude  De  Preval  for providing  unpublished  data  and  for helpful 
discussions and Chantal Mattmann for technical assistance. 
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